1. France Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Vetoquinol S.A.

Vetoquinol S.A.

VETO.PA
Vetoquinol S.A.undefined flagEuronext Paris
71.20
EUR
-0.10
- -
827.67MMarket Cap
Vetoquinol S.A.
VETO.PA
(Euronext Paris)

Recent

price

71.20

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
FRC
25.11
24.27
25.22
25.31
26.58
28.88
29.55
29.7
31.07
33.47
36.15
44.07
45.62
44.73
45.71
45.23
Revenue per Share
1.98
1.94
1.91
1.99
2.17
2.04
2.35
2.94
3.06
2.42
1.63
5.31
4.06
4.7
4.98
4.94
Basic EPS, GAAP
2.37
1.74
2.12
1.74
2.54
2.14
2.5
2.32
2
3.19
-4.5
3.27
3.41
5.95
5.78
4.42
Free Cash Flow per Basic Share
0.29
0.3
0.33
0.35
0.37
0.39
0.41
0.43
0.46
0.48
0.38
0.5
0.8
0.8
0.85
0.9
Dividend per Share
7.4
4.48
4.42
4.5
4.68
4.54
4.85
5.44
5.57
4.93
4.14
7.83
6.57
7.21
7.49
7.49
Book Value per Share
8.73
10.52
10.85
12.19
12.2
13.9
16.13
18.33
20.23
18.05
9.89
15.17
20.27
25.19
30.3
33.63
Tangible Book Value per Share
11
12
12
12
12
12
12
12
12
12
12
12
12
12
12
12
Basic Weighted Avg Shares
282
284
298
300
315
343
350
352
368
396
427
521
540
529
539
526
Sales/Revenue/Turnover
10.89
11.19
10.67
11.3
11.25
11.62
12.02
12.98
13.14
11.63
13.19
16.47
15.61
14.69
14.15
14.97
Operating Margin (%)
12
12
12
12
13
18
16
12
12
24
46
5
42
35
31
34
Depreciation Expense
22
23
23
24
26
24
28
35
36
29
19
63
48
56
59
57
Net Income, GAAP
26.59
29.17
26.21
26.8
31.56
33.73
29.73
19.31
25.05
30.64
46.76
27.48
34.02
27.75
27.57
28.57
Effective Tax Rate (%)
7.89
7.99
7.57
7.87
8.17
7.05
7.94
9.89
9.85
7.22
4.5
12.06
8.89
10.5
10.88
10.91
Profit Margin (%)
65
94
106
115
138
149
165
173
190
165
68
117
168
224
280
309
Working Capital
- -
16
22
11
38
24
15
7
- -
7
8
7
10
10
11
8
LT Debt
184
211
228
236
268
289
316
336
363
386
372
441
485
527
576
591
Total Equity
10.99
9.17
8.28
8.33
7.5
7.53
8.23
9.84
9.33
7.74
6.23
11.97
10.63
9.98
9.04
8.71
Return on Invested Capital (%)
21.77
23.19
24.72
24.85
25.76
24.6
33.19
43.28
47.73
40.94
16.12
44.91
47.87
56.73
55.94
54.97
Return on Capital (%)
27.46
33.5
43.12
44.68
47.38
44.19
49.96
57.07
55.57
46.02
35.85
88.85
56.38
68.19
67.59
65.38
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
7.54%
9.84%
2.69%
Free Cash Flow
-30.83%
-24.4%
-24.65%
Net Income, GAAP
21.31%
44.5%
-2.26%
Sales/Revenue/Turnover
4.57%
4.58%
-2.51%
Total Cash Common Dividend
- -
- -
3.42%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
529
2024
- -
- -
- -
- -
539
2025
- -
- -
- -
- -
526

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
4.7
2024
- -
- -
- -
- -
4.98
2025
- -
- -
- -
- -
4.94

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
0.8
2024
- -
- -
- -
- -
0.85
2025
- -
- -
- -
- -
0.9
Similar Companies
Fusen Pharmaceutical Company Limited (1652.HK)
Heritage Cannabis Holdings Corp. (HERTF)
XPhyto Therapeutics Corp. (4XT.DE)
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (600196.SS)
Jinghua Pharmaceutical Group Co., Ltd. (002349.SZ)
Kaken Pharmaceutical Co., Ltd. (KKPCF)
Business
Vetoquinol S.A. operates as a global animal health enterprise, engaging in the research, development, production, and distribution of veterinary medications and non-medicinal offerings across Europe, the Americas, Africa, the Middle East, Asia, and Oceania. The company’s extensive product line addresses critical areas such as pain, mobility, and inflammation management; dermatology, hygiene, and overall care; parasitic infections; udder health; various infectious diseases; reproductive health; behavior modification; internal medicine; and cardiology-nephrology solutions. These diverse products are tailored for a wide array of animal species, including companion animals like dogs and cats, as well as livestock such as cattle, pigs, and poultry. Established in 1933 and based in Lure, France, Vetoquinol, a subsidiary of Soparfin SCA, maintains a strategic focus on innovation and its high-growth "Essentials" product portfolio, which continues to drive its performance, with annual sales reaching €539 million in 2024.